Once-a-Day Patch,
All-Day Relief

Licart® has unique patented drug patch technology for once-a-day treatment of acute pain due to minor strains, sprains, and contusions.

Checkmark

Targeted

Delivers medicine directly to where it hurts

Checkmark

Fast-Acting

Significant pain relief within 1-3 hours after first application1

Checkmark

Long-Lasting

Delivers NSAID power for up to 24 hours2

Checkmark

Well-Tolerated

Low incidence of adverse events3

LEARN MORE ABOUT LICART

With the Licart Copay Savings Card, commercially insured patients can receive instant savings when purchasing Licart at any retail pharmacy.

GET YOUR SAVINGS CARD

*Attention Patient: Present this voucher to your pharmacist, along with your insurance card and valid prescription. Keep this voucher for future savings on your refill prescriptions. With the use of this voucher, insured patients with a prescription drug plan should pay as little as $15 for each prescription. Maximum benefit limits apply and are subject to change at any time.

Licart Direct is a convenient program based on a network of participating mail-order pharmacies that will deliver your prescription right to your doorstep. Licart Direct provides you with a low cash price, regardless of health insurance status.

SAVE TODAY

What Makes Licart Different?

Licart® (diclofenac epolamine) topical system 1.3% is the only once-a-day topical nonsteroidal anti-inflammatory drug (NSAID) therapy available for acute pain due to minor strains, sprains, and contusions. Its patented next-generation patch technology goes to work fast for powerful pain relief that starts within 1-3 hours of application and can last all day with once-daily dosing.4

Licart delivers medicine directly to where it hurts and has a low incidence of adverse events.3

HOW TO USE LICART

**Acertis Pharmaceuticals LLC (“Acertis”) has licensed the exclusive US distribution rights for Licart® (diclofenac epolamine) topical system 1.3% from Institut Biochimique SA (IBSA)

Offer not valid for patients enrolled in government health plans (Medicare, Medicaid, VA/DOD, etc.).”

Licart vs. Other NSAID Pain Relievers

  Licart® Flector®
(diclofenac epolamine) topical system 		Diclofenac 1% gel OTC Diclofenac sodium topical solution 2.0% Oral pain relievers†,††
24-hour, once-a-day pain relief dosing checkmark        
Pain relief within 1-3 hours of medication checkmark       checkmark
Mess-free patch checkmark checkmark      
Localized absorption of active ingredient checkmark checkmark checkmark checkmark  
Not habit-forming checkmark checkmark checkmark checkmark checkmark
Prescription strength checkmark checkmark   checkmark checkmark

† Nonprescription
†† Includes acetaminophen, ibuprofen, naproxen, etc.

Put Licart Where It Hurts

Licart is easy to use. Simply peel it from its adhesive backing, and apply it to where it hurts. Licart is mess-free, has no unpleasant odor, and will not stain clothes.
To learn more about using Licart, click here.

APPLICATION INSTRUCTIONS

FOOT

BACK

NECK

SHOULDER

WRIST

ELBOW

ANKLE

KNEE

INTERESTED IN TRYING LICART?

Let Us Help

Stethoscope
TALK TO YOUR DOCTOR
Piggy bank
WAYS TO SAVE
Read More ↗

INDICATIONS AND USAGE

LICART contains diclofenac epolamine, which is a nonsteroidal anti-inflammatory drug (NSAID), and is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions.

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF SERIOUS CARDIOVASCULAR and GASTROINTESTINAL EVENTS

Cardiovascular Thrombotic Events

  • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in the treatment and may increase with duration of use.
  • LICART is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.

Gastrointestinal Bleeding, Ulceration, and Perforation

  • NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events, including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events.

CONTRAINDICATIONS

LICART is contraindicated in the following patients:

  • Known hypersensitivity to diclofenac or any components of the drug product.
  • History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs.
  • In the setting of CABG surgery.
  • For use on non-intact or damaged skin.

WARNINGS AND PRECAUTIONS

  • Hepatotoxicity: Inform patients of warning signs and symptoms of hepatotoxicity. Discontinue if abnormal liver tests persist or worsen or if clinical signs and symptoms of liver disease develop.
  • Hypertension: Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. Monitor blood pressure.
  • Heart Failure and Edema: Avoid use of LICART in patients with severe heart failure unless benefits are expected to outweigh risk of worsening heart failure.
  • Renal Toxicity: Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia. Avoid use of LICART in patients with advanced renal disease unless benefits are expected to outweigh risk of worsening renal function.
  • Anaphylactic Reactions: Seek emergency help if an anaphylactic reaction occurs.
  • Exacerbation of Asthma Related to Aspirin Sensitivity: LICART is contraindicated in patients with aspirin-sensitive asthma. Monitor patients with preexisting asthma (without aspirin sensitivity).
  • Serious Skin Reactions: Discontinue LICART at first appearance of skin rash or other signs of hypersensitivity.
  • Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): Discontinue and evaluate clinically.
  • Fetal Toxicity: Limit use of NSAIDs, including LICART, between about 20 to 30 weeks in pregnancy due to the risk of oligohydramnios/fetal renal dysfunction. Avoid use of NSAIDs in women at about 30 weeks' gestation and later in pregnancy due to the risks of oligohydramnios/fetal renal dysfunction and premature closure of the fetal ductus arteriosus.
  • Hematologic Toxicity: Monitor hemoglobin or hematocrit in patients with any signs or symptoms of anemia.

ADVERSE REACTIONS

Most common adverse reactions for LICART are application site pruritus and other application site reactions.
To report SUSPECTED ADVERSE REACTIONS, contact IBSA Pharma Inc. at: 1-800-587-3513 or FDA at 1-800-FDA-1088 or fda.gov/medwatch.
For Full Prescribing Information, visit licart.com/wp-content/uploads/2023/10/Licart-Full-Prescribing-Information_2024.pdf.

Scroll to Top